Evaluation of liver diseases in Iranian patients with primary antibody deficiencies

Annals of Hepatology

Volumn 8, Issue 3, 2009, Pages 196-202

  Motamed, Farzaneh ^a   Aghamohammadi, Asghar ^a,b   Soltani, Mahmoud ^a   Mansouri, Mahboubeh ^d   Rezaei, Nima ^a,b   Teimourian, Shahram ^b   Pouladi, Nima ^b   Abdollahzadeh, Sina ^a   Parvaneh, Nima ^a,c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c PASTEUR INSTITUTE OF IRAN   (Iran)

^d SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Chronic active hepatitis; HCV infection; Liver disease; Primary antibody deficiency

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; VIRUS RNA;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHILD; CHRONIC ACTIVE HEPATITIS; CHRONIC LIVER DISEASE; CLINICAL EXAMINATION; CLINICAL FEATURE; CONTROLLED STUDY; CRYPTOSPORIDIUM PARVUM; DISEASE ASSOCIATION; ETHNIC GROUP; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEPATITIS C VIRUS; HEPATOMEGALY; HISTOPATHOLOGY; HUMAN; HUMORAL IMMUNE DEFICIENCY; HYPER IGM SYNDROME; IRANIAN; LIVER BIOPSY; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRESCHOOL CHILD; SCHOOL CHILD; SCLEROSING CHOLANGITIS; SCREENING TEST; TOXIC HEPATITIS; VIRUS IDENTIFICATION; ETHNOLOGY; HEPATITIS C; IMMUNE DEFICIENCY; IRAN; LIVER CIRRHOSIS; MIDDLE AGED; PREVALENCE; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; IRAN; LIVER CIRRHOSIS; LIVER DISEASES; MALE; MIDDLE AGED; PREVALENCE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 77749253766     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31765-x     Document Type: Article

References (44)

1. Aghamohammadi A, Moein M, Farhoudi A, Pourpak Z, Re-zaei N, Abolmaali K, et al. Primary immunodeficiency in Iran: first report of the National Registry of PID in Children and Adults. J Clin Immunol 2002; 22: 375-380.
2. Knerr V, Grimbacher B. Primary immunodeficiency registries. Curr Opin Allergy Clin Immunol 2007; 7: 475-480.
3. Rezaei N, Aghamohammadi A, Moin M, Pourpak Z, Movahedi M, Gharagozlou M, et al. Frequency and clinical manifestations of patients with primary immunodeficiency disorders in Iran: update from the Iranian Primary Immunodeficiency Registry. J Clin Immunol 2006; 26: 519-532.
4. Notarangelo L, Casanova JL, Fischer A, Puck J, Rosen F, Seger R, Geha R. Primary immunodeficiency diseases: An update. Journal of Allergy & Clinical Immunology 2004; 114: 677-687.
5. Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol 1999; 92: 34-48.
6. Lederman HM, Winkelstein JA. X-linked agammaglobuline-mia: an analysis of 96 patients. Medicine (Baltimore) 1985; 64: 145-56.
7. Aghamohammadi A, Farhoudi A, Moin M, Rezaei N, Kouhi A, Pourpak Z, et al. Clinical and immunological features of 65 Iranian patients with common variable immunodeficiency. Clin Diagn Lab Immunol 2005; 12: 825-832.
8. Moin M, Aghamohammadi A, Farhoudi A, Pourpak Z, Rezaei N, Movahedi M, et al. X-linked agammaglobulinemia: a survey of 33 Iranian patients. Immunol Invest 2004; 33: 81-93.
9. Hermaszewski RA, Webster AD. Primary hypogammaglobu-linaemia: a survey of clinical manifestations and complications. Q J Med 1993; 86: 31-42.
10. Farhoudi A, Aghamohammadi A, Moin M, Rezaei N, Pourpak Z, Movahedi M, et al. Distribution of primary immunodeficiency disorders diagnosed in the Children's Medical Center in Iran. J Investig Allergol Clin Immunol 2005; 15: 177-182.
11. Aghamohammadi A, Moazzami K, Rezaei N, Karimi A, Mova-hedi M, Gharagozlou M, et al. ENT manifestations in Iranian patients with primary antibody deficiencies. J Laryngol Otol 2008; 122: 409-413.
12. Aghamohammadi A, Parvaneh N, Tirgari F, Mahjoob F, Mova-hedi M, Gharagozlou M, et al. Lymphoma of mucosa-associa-ted lymphoid tissue in common variable immunodeficiency. Leuk Lymphoma 2006; 47: 343-346.
13. Aghamohammadi A, Pouladi N, Parvaneh N, Yeganeh M, Mo-vahedi M, Gharagolou M, et al. Mortality and morbidity in common variable immunodeficiency. J Trop Pediatr 2007; 53: 32-38.
14. Bjoro K, Haaland T, Skaug K, Froland SS. The spectrum of hepatobiliary disease in primary hypogammaglobulinaemia. J Intern Med 1999; 245: 517-524.
15. Fiore M, Ammendola R, Gaetaniello L, De Felice C, Iorio R, Vegnente A, et al. Chronic unexplained liver disease in children with primary immunodeficiency syndromes. J Clin Gastroenterol 1998; 26: 187-192.
16. Rodrigues F, Davies EG, Harrison P, McLauchlin J, Karani J, Portmann B, et al. Liver disease in children with primary immunodeficiencies. J Pediatr 2004; 145: 333-339.
17. Seymour B, Miles J, Haeney M. Primary antibody deficiency and diagnostic delay. J Clin Pathol 2005; 58: 546-547.
18. Khodadad A, Aghamohammadi A, Parvaneh N, Rezaei N, Ma-hjoob F, Bashashati M, et al. Gastrointestinal manifestations in patients with common variable immunodeficiency. Dig Dis Sci 2007; 52: 2977-2983.
19. Rezaei N, Aghamohammadi A, Siadat SD, Nejati M, Ahmadi H, Moin M, et al. Serum bactericidal antibody response to serogroup C polysaccharide meningococcal vaccination in children with primary antibody deficiencies. Vaccine 2007; 25: 5308-5314.
20. Aghamohammadi A, Moin M, Farhoudi A, Rezaei N, Pourpak Z, Movahedi M, et al. Efficacy of intravenous immunoglo-bulin on the prevention of pneumonia in patients with aga-mmaglobulinemia. FEMS Immunol Med Microbiol 2004; 40: 113-118.
21. Busse PJ, Razvi S, Cunningham-Rundles C, Cunningham-Run-dles C. Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. J Allergy Clin Immunol 2002; 109: 1001-1004.
22. Chapel HM. Consensus on diagnosis and management of primary antibody deficiencies. Consensus Panel for the Diagnosis and Management of Primary Antibody Deficiencies. BMJ 1994; 308(6928): 581-585.
23. Davis JJ, Heyman MB, Ferrell L, Kerner J, Kerlan R, Jr., Thaler MM. Sclerosing cholangitis associated with chronic cryptosporidiosis in a child with a congenital immunodeficiency disorder. Am J Gastroenterol 1987; 82: 1196-202.
24. DiPalma JA, Strobel CT, Farrow JG. Primary sclerosing cho-langitis associated with hyperimmunoglobulin M immunodeficiency (dysgammaglobulinemia). Gastroenterology 1986; 91: 464-468.
25. Bjoro K, Froland SS, Yun Z, Samdal HH, Haaland T. Hepatitis C infection in patients with primary hypogammaglobuli-nemia after treatment with contaminated immune globulin. N Engl J Med 1994; 331: 1607-1611.
26. Chapel HM, Christie JM, Peach V, Chapman RW. Five-year follow-up of patients with primary antibody deficiencies following an outbreak of acute hepatitis C. Clin Immunol 2001; 99: 320-324.
27. Rossi G, Tucci A, Cariani E, Ravaggi A, Rossini A, Radaeli E. Outbreak of hepatitis C virus infection in patients with hematologic disorders treated with intravenous immunog-lobulins: different prognosis according to the immune status. Blood 1997; 90: 1309-1314.
28. Yap PL, McOmish F, Webster AD, Hammarstrom L, Smith CI, Bjorkander J, et al. Hepatitis C virus transmission by intravenous immunoglobulin. J Hepatol 1994; 21: 455-460.
29. McLauchlin J, Amar CF, Pedraza-Diaz S, Mieli-Vergani G, Hadzic N, Davies EG. Polymerase chain reaction-based diagnosis of infection with Cryptosporidium in children with primary immunodeficiencies. Pediatr Infect Dis J 2003; 22: 329-335.
30. Knight AK, Cunningham-Rundles C. Inflammatory and autoimmune complications of common variable immune deficiency. Autoimmunity Reviews 2006; 5: 156-159.
31. Zelazko M, Carneiro-Sampaio M, Cornejo de Luigi M, Garcia de Olarte D, Porras Madrigal O, Berron Perez R, et al. Primary immunodeficiency diseases in Latin America: first report from eight countries participating in the LAGID. Latin American Group for Primary Immunodeficiency Diseases. J Clin Immunol 1998; 18: 161-166.
32. Webster AD, Brown D, Franz A, Dusheiko G. Prevalence of hepatitis C in patients with primary antibody deficiency. Clin Exp Immunol 1996; 103: 5-7.
33. Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Su-gai Y, et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 1992; 73(Pt 3): 673-679.
34. Garson JA, Ring C, Tuke P, Tedder RS. Enhanced detection by PCR of hepatitis C virus RNA. Lancet 1990; 336: 878-879.
35. Naveh Y, Mendelsohn H, Spira G, Auslaender L, Mandel H, Berant M. Primary sclerosing cholangitis associated with immunodeficiency. Am J Dis Child 1983; 137: 114-117.
36. Levy J, Espanol-Boren T, Thomas C, Fischer A, Tovo P, Bor-digoni P, et al. Clinical spectrum of X-linked hyper-IgM syndrome. J Pediatr 1997; 131: 47-54.
37. Rodrigues F, Davies EG, Harrison P, McLauchlin J, Karani J, Portmann B, et al. Liver disease in children with primary immunodeficiencies. J Pediatr 2004; 145: 333-399.
38. Quinti I, Pierdominici M, Marziali M, Giovannetti A, Don-nanno S, Chapel H, et al. European surveillance of immuno-globulin safety-results of initial survey of 1243 patients with primary immunodeficiencies in 16 countries. Clin Immunol 2002; 104: 231-236.
39. Yoshioka R, Sato Y, Kogure A, Ohira H, Takagi T, Kuroda M, et al. Association of primary sclerosing cholangitis, thymoma and hypogammaglobulinemia. Liver 1995; 15: 53-55.
40. Gremse DA, Bucuvalas JC, Bongiovanni GL. Papillary stenosis and sclerosing cholangitis in an immunodeficient child. Gastroenterology 1989; 96: 1600-1603.
41. Behrman RE, Kliegman R, Jenson HB. Nelson textbook of pediatrics. 17th Ed. Philadelphia, PA: Saunders; 2004.
42. Bjoro K, Skaug K, Haaland T, Froland SS. Long-term outcome of chronic hepatitis C virus infection in primary hypo-gammaglobulinaemia. Q J Med 1999; 92: 433-441.
43. Stiehm ER. Human intravenous immunoglobulin in primary and secondary antibody deficiencies. Pediatr Infect Dis J 1997; 16: 696-707.
44. Vento S, Cainelli F, Renzini C, Concia E. Autoimmune hepatitis type 2 induced by HCV and persisting after viral clearance. Lancet 1997; 350: 1298-1299.